Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a clinical stage drug development company is making the right moves. The recent financial performance of the company as well as results from ongoing clinical trials has attracted both investors as well as analysts. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shares after opening at $4.72 moved to $5.00 on last trade day and at the end of the day closed at $4.45. Company price to sales ratio in past twelve months was calculated as 54.04 and price to cash ratio as 1.84. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) showed a negative weekly performance of -6.32%.
Aquinox Pharmaceuticals (NASDAQ:AQXP) major shareholder Pfizer Inc purchased 272,727 shares of Aquinox Pharmaceuticals stock in a transaction dated Wednesday, March 12th. The stock was purchased at an average price of $11.00 per share, with a total value of $2,999,997.00. Following the purchase, the insider now directly owns 1,235,330 shares in the company, valued at approximately $13,588,630. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) shares fell -3.48% in last trading session and ended the day on $13.02. AQXP return on equity ratio is recorded as 60.90% and its return on assets is -316.70%.
Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, announced financial results and recent key operational highlights for the three months and full year ended December 31, 2013.Sophiris Bio Inc (NASDAQ:SPHS) shares moved down -3.47% in last trading session and was closed at $3.62, while trading in range of $3.54-$3.88. Sophiris Bio Inc (NASDAQ:SPHS) year to date performance is -2.16%.
The Telik, Inc. (NASDAQ:TELK) believes its existing capital resources are only sufficient to support operations through approximately May 2014. The timing remains uncertain, however, and may change as we continue efforts to further conserve resources and/or reducing expenses. In order to continue operations, Telik will require substantial financing in the very near term. Although the company has been able to raise funds through its At Market Issuance Sales Agreement, there is no assurance Telik will be successful in obtaining additional funding in the future. To this end, the financial advisory firm retained by Telik continues to seek capital and to explore and recommend strategic alternatives through which the value of its assets to stockholders could be optimized.Telik, Inc. (NASDAQ:TELK) weekly performance is -2.14%. On last trading day company shares ended up $1.37. Telik, Inc. (NASDAQ:TELK) distance from 50-day simple moving average is -1.82%. Analysts mean target price for the company is $1.05.